IMPORTANT SAFETY INFORMATION
-
Last revised: February 19, 2025
Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo the same safety, effectiveness, or manufacturing reviews as FDA-approved medications. Your medical provider may recommend certain doses of compounded semaglutide based on your medical evaluation.
Indications and Use
Compounded semaglutide is an injectable prescription medicine that may help adults with obesity or excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.
Compounded semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced-calorie diet and increased physical activity, for individuals with an initial body mass index (BMI) of:
30 kg/m² or greater (obesity)
27 kg/m² or greater (overweight) with at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Compounded semaglutide should not be used with other semaglutide-containing products or any GLP-1 receptor agonist medicines.
It is not known if semaglutide is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products.
It is not known if semaglutide can be used in people who have had pancreatitis.
It is not known if semaglutide is safe and effective for use in children under 18 years of age.
Important Safety Information for Compounded Semaglutide Injection
Warning: Risk of Thyroid C-Cell Tumors
In animal studies, semaglutide caused thyroid tumors, including thyroid cancer. It is not known if compounded semaglutide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.
Tell your provider immediately if you experience:
A lump or swelling in your neck
Hoarseness
Trouble swallowing
Shortness of breath
These may be symptoms of thyroid cancer.
Do not use compounded semaglutide if:
You or your family have ever had medullary thyroid carcinoma (MTC).
You have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Is Compounded Semaglutide FDA-Approved?
Compounded semaglutide is not FDA-approved and does not undergo the same rigorous efficacy and safety checks as FDA-approved medications.
Limitations of Use
Should not be used in combination with other semaglutide-containing products or GLP-1 receptor agonists.
The safety and efficacy of coadministration with other weight loss products have not been established.
Has not been studied in patients with a history of pancreatitis.
Compounded medications are not FDA-approved and do not have the same indications for treatment as FDA-approved medications. These recommendations for compounded semaglutide apply while FDA-approved therapies remain on shortage.
Who Should Not Use Compounded Semaglutide?
Do not use compounded semaglutide if:
You or your family have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have a known allergic reaction to compounded semaglutide.
How Should Compounded Semaglutide Be Administered?
Take compounded semaglutide with or without food.
Self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day each week.
Your medical provider will guide you on a treatment regimen, which may include dose increases every four weeks.
Do not change your dosing regimen or stop taking compounded semaglutide without speaking to your provider.
What Should I Tell My Medical Provider Before Using Compounded Semaglutide?
Tell your provider about all the medications you are currently taking, including:
Diabetes medications, including insulin or sulfonylureas (e.g., Amaryl, Glucotrol XL)
Other GLP-1 medications, including Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro, Victoza, Byetta, or Bydureon
Any other weight-loss products, including dietary supplements
Medical history to discuss with your provider:
Type 1 or type 2 diabetes
Thyroid cancer
Pancreatitis
Kidney disease
Diabetic retinopathy
Depression or suicidal thoughts
Pregnancy and Breastfeeding Considerations:
Compounded semaglutide should not be used during pregnancy as it may harm the unborn baby.
Discontinue use at least two months before a planned pregnancy.
If breastfeeding, consult your provider, as compounded semaglutide has been found in the milk of lactating rats.
Withholding or providing inaccurate health information can result in serious harm, including death.
Serious Side Effects to Monitor
Seek immediate medical attention if you experience:
Thyroid C-Cell Tumors – Lump or swelling in the neck, hoarseness, trouble swallowing, shortness of breath
Pancreatitis – Severe abdominal pain that does not go away, pain radiating to the back, vomiting
Gallbladder Disease – Upper stomach pain, jaundice, fever, clay-colored stools
Low Blood Sugar (Hypoglycemia) – Dizziness, blurred vision, mood changes, sweating, fast heartbeat
Kidney Injury – Dehydration, nausea, vomiting
Serious Allergic Reactions – Swelling, rash, rapid heartbeat, breathing issues
Diabetic Retinopathy Complications – Vision changes
Increase in Heart Rate – Racing heartbeat while at rest
Suicidal Behavior and Ideation – Sudden mood or behavior changes
Never share pens or needles, as sharing increases the risk of infection.
Most Common Side Effects of Compounded Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Stomach pain
Indigestion
Injection site reactions
Fatigue
Hair loss
Heartburn (GERD)
Report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.
Before Using Compounded Semaglutide
Discuss with your provider if you have:
Problems with your pancreas or kidneys
Severe stomach problems, such as gastroparesis
Diabetes and take insulin or sulfonylureas
A history of diabetic retinopathy
If you take birth control pills, consult your provider before using compounded semaglutide, as birth control pills may be less effective.
Legal Disclaimer
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly. Lovely Meds has no affiliation with Novo Nordisk or Eli Lilly.
-
Oral Semaglutide GLP-1
*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.
WARNING
Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:
Severe nausea and/or vomiting resulting in dehydration - it is important to stay well hydrated and drink plenty of fluids while on this medication.
Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis.
Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below).
Pancreatitis: Severe pain in your abdomen or back that will not go away.
Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
Hepatitis/Elevated liver enzymes/Jaundice
Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy.
Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
Increasing heart rate
Worsening depression, behavior changes, or suicidality
Never share the semaglutide with other people
Drug Interactions
As with other medications, oral semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Oral semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting oral semaglutide, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on oral semaglutide.
Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.
To report suspected adverse reactions to o semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
In case of emergencies, please call 911 or go to the nearest emergency room.
Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
-
Indications: Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Contraindications: Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should not be used in patients with a history of severe gastrointestinal disease, including gastroparesis.
Warnings and Precautions:
Risk of Thyroid C-Cell Tumors: Cases of MTC have been reported in patients treated with GLP-1 receptor agonists, including tirzepatide. Patients should be assessed for risk factors prior to initiation and monitored for signs and symptoms of thyroid tumors.
Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported with GLP-1 receptor agonists. Patients should be informed of the characteristic symptoms of pancreatitis and advised to discontinue tirzepatide and seek medical attention if symptoms occur.
Hypoglycemia with Concomitant Use of Insulin and Insulin Secretagogues: The risk of hypoglycemia is increased when tirzepatide is used in combination with insulin or insulin secretagogues. Dose adjustments may be required to minimize the risk.
Acute Kidney Injury: Cases of acute renal failure and worsening of chronic renal failure have been reported with GLP-1 receptor agonists. Patients should be monitored for changes in renal function, and caution should be exercised in patients with renal impairment.
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported with tirzepatide. If a hypersensitivity reaction occurs, discontinue tirzepatide and initiate appropriate medical treatment.
Gastrointestinal Adverse Reactions: Nausea, vomiting, diarrhea, and constipation may occur with tirzepatide. These adverse reactions may decrease over time or with dose reduction.
Adverse Reactions:The most common adverse reactions (≥5%) associated with tirzepatide include nausea, vomiting, diarrhea, abdominal pain, and constipation.
Pregnancy and Lactation: Tirzepatide should not be used during pregnancy as it may cause fetal harm. It is unknown whether tirzepatide is excreted in human milk, and caution should be exercised when administering tirzepatide to breastfeeding women.
Drug Interactions:Caution should be exercised when co-administering tirzepatide with other drugs that affect gastrointestinal motility or absorption, as well as drugs that may increase the risk of hypoglycemia.
Patient Counseling Information:Patients should be counseled on the risks and benefits of tirzepatide therapy, including the potential for gastrointestinal adverse reactions, hypoglycemia, and the importance of adherence to diet and exercise. Patients should also be educated on the signs and symptoms of thyroid tumors, pancreatitis, and hypersensitivity reactions.
-
Important Safety Information for Zepbound (tirzepatide) injection
Warning: Risk of Thyroid C-Cell Tumors
In rats, Zepbound caused thyroid tumors, including thyroid cancer. It is not known if Zepbound will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
What is the FDA-approved use of Zepbound?
Zepbound is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
30 kg/m^2 or greater (obesity) or
27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).
Limitations of Use:
Zepbound should not be used in combination with other tirzepatide-containing products or any other GLP-1 receptor agonist.
The safety and efficacy of coadministration with other products for weight management have not been established.
Zepbound has not been studied in patients with a history of pancreatitis.
Who should not use Zepbound?
Do not use Zepbound if:
You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have a known allergic reaction to Zepbound.
How should I take Zepbound?
You can take Zepbound with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Good Life-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Zepbound as prescribed without discussing with your provider first.
What should I tell my Good Life-affiliated provider before using Zepbound?
Zepbound has certain drug interactions. It’s important to tell your Good Life-affiliated provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
Some medications to watch out for include:
Medications for diabetes: Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)
Other oral medications: Zepbound causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.
Hormonal birth control: If you are using an oral hormonal contraceptive (birth control), Zepbound may decrease its efficacy, especially after the first dose. Switch to a non-oral contraceptive method or use a barrier method of contraception for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation, until you reach a maintenance dose.
Other GLP-1 medications: Including Mounjaro, Wegovy, Ozempic, Saxenda, Victoza, Byetta, or Bydureon. These medications should not be taken with Zepbound.
Other products for weight loss: Including dietary supplements
It’s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:
Type 1 or type 2 diabetes
Thyroid cancer
Gastrointestinal disease
Pancreatitis
Kidney disease
Diabetic retinopathy
Depression
Suicidal thoughts or behavior
Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.
If you are pregnant: Zepbound should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Zepbound during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
If you are a female reproductive potential: Zepbound may reduce the efficacy of oral hormonal contraceptives. Switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after starting medication and for 4 weeks after each dose escalation until you reach a maintenance dose.
If you are breastfeeding: It is not known if Zepbound passes into breast milk. Talk to your provider first about the benefits and risks of using Zepbound while breastfeeding.
Pregnancy registry: There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound during pregnancy. Pregnant patients exposed to Zepbound and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
What are the most serious side effects that I or a caregiver should monitor for when taking Zepbound?
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
These serious side effects are rare, but can occur with Zepbound. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.
Thyroid C-Cell Tumors: In rats, Zepbound caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors. It is unknown whether Zepbound causes thyroid C-cell tumors in humans. Zepbound is contraindicated in patients with a family history of medullary thyroid cancer (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Severe Gastrointestinal Disease: Zepbound is associated with gastrointestinal side effects, such as nausea, diarrhea, vomiting, constipation, and stomach pain, and can sometimes be severe. It hasn’t been studied in patients with severe gastrointestinal disease and isn’t recommended in these patients. The majority of nausea, vomiting, and/or diarrhea events occurred during a dose increase and decreased over time.
Acute Kidney Injury: Gastrointestinal side effects of Zepbound like diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems if dehydration is severe. It is important for you to drink plenty of water to help reduce your chance of dehydration.
Acute Gallbladder Disease: Zepbound, other GLP-1 receptor agonists, and weight loss are associated with an increased chance of acute gallbladder disease. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Allergic Reactions: Stop using Zepbound right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Low Blood Sugar (Hypoglycemia): Zepbound lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Rapid improvement of glucose control has been associated with temporary worsening of diabetic retinopathy. Tell your provider right away if you experience changes in vision.
Suicidal Behavior and Ideation: You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
Never Share a Pen: Pen-sharing poses a risk of infection.
What are the most common side effects of Zepbound?
Nausea
Diarrhea
Vomiting
Constipation
Stomach pain
Indigestion
Injection site reactions
Feeling tired
Allergic reactions
Belching
Hair loss
Gastroesophageal reflux disease (heartburn)
You are encouraged to report negative side effects of prescription products to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
This information is not comprehensive. Please see the full Prescribing Information for complete safety information.
-
Important Safety Information for Wegovy (semaglutide) injection
Warning: Risk of Thyroid C-Cell Tumors
In studies with mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused thyroid tumors, including thyroid cancer. It is not known if Wegovy will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use Wegovy if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
What is the FDA-approved use of Wegovy?
Wegovy is used to reduce excess body weight and maintain weight reduction long term, when used with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of:
30 kg/m2 or greater (obesity) or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
Wegovy is also used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with known cardiovascular disease and with either obesity or overweight.
Limitations of Use:
Wegovy should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist
Who should not use Wegovy?
Do not use Wegovy if:
You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have a known allergic reaction to semaglutide (the active ingredient in Wegovy or Ozempic).
How should Wegovy be administered?
You can take Wegovy with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Good LIfe-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Wegovy as prescribed without discussing with your provider first.
What should I tell my Good Life-affiliated provider before using Wegovy?
Wegovy has certain drug interactions. It’s important to tell your Good Life-affiliated provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
Some medications to watch out for include:
Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)
Wegovy causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.
Other medications in the GLP-1 medication class, including Ozempic, Saxenda, Victoza, Byetta, or Bydureon
If you’re using other products for weight loss, including dietary supplements
It’s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:
Type 1 or type 2 diabetes
Thyroid cancer
Pancreatitis
Kidney disease
Diabetic retinopathy
Depression
Suicidal thoughts or behavior
Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.
If you are pregnant: Wegovy should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Wegovy during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
If you are a female or male of reproductive potential: Discontinue Wegovy at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.
If you are breastfeeding: Wegovy was found in the milk of lactating rats. Tell your Good Life-affiliated provider if you are breastfeeding before you start Wegovy.
Pregnancy registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide (the active ingredient in Wegovy and Ozempic) during pregnancy. Pregnant women exposed to semaglutide and healthcare providers are encouraged to contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com.
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
What are the most serious side effects that I or a caregiver should monitor for when taking Wegovy?
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
These serious side effects can occur with Wegovy. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.
Thyroid C-Cell Tumors: In mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Wegovy causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza and Saxenda) after the drug was put on the market. Wegovy is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Acute Gallbladder Disease: Wegovy may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Low Blood Sugar (hypoglycemia): Wegovy lowers blood glucose. It can cause too low blood sugar in patients who take Wegovy with another glucose control medication, including insulin. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Acute Kidney Injury: In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.
Serious Allergic Reactions: Stop using Wegovy right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: If you have type 2 diabetes, tell your provider right away if you experience changes in vision.
Increase in Heart Rate: Tell your provider right away if you have a racing heartbeat while at rest.
Suicidal Behavior and Ideation: You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
Never Share a Pen: Pen-sharing poses a risk of infection.
What are the most common side effects of Wegovy?
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Headache
Fatigue
Dyspepsia
Dizziness
Abdominal distension
Belching
Hypoglycemia in patients with type 2 diabetes
Flatulence
Gastroenteritis
Gastroesophageal reflux disease
You are encouraged to report negative side effects of prescription products:
Contact Novo Nordisk Inc. at 1-833-934-6891
Contact FDA MedWatch at 1-800-FDA-1088 or visit www.fda.gov/medwatch
This information is not comprehensive. Please see the full Prescribing Information for complete safety information.
-
Important Safety Information for Ozempic (semaglutide) injection
Warning: Risk of Thyroid C-Cell Tumors
In studies with mice and rats, semaglutide (the active ingredient in Ozempic and Wegovy) caused thyroid tumors, including thyroid cancer. It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use Ozempic if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
What is the FDA-approved use of Ozempic?
Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used:
with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus and established cardiovascular disease.
Limitations of Use:
Ozempic has not been studied in patients with a history of pancreatitis.
Ozempic is not for treatment of type 1 diabetes mellitus.
Your Good Life-affiliated provider may recommend the use of Ozempic as treatment for chronic weight management (obesity or overweight).
Who should not use Ozempic?
Do not use Ozempic if:
You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have a known allergic reaction to semaglutide (the active ingredient in Wegovy or Ozempic).
How should Ozempic be administered?
You can take Ozempic with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Good Life-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Ozempic as prescribed without discussing with your provider first.
What should I tell my Good Life-affiliated provider before using Ozempic?
Ozempic has certain drug interactions. It’s important to tell your Good Life-affiliated provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
Some medications to watch out for include:
Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)
Ozempic causes a delay in gastric emptying so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.
Other GLP-1 medications, including Wegovy, Saxenda, Victoza, Byetta, or Bydureon
If you’re using other products for weight loss, including dietary supplements
It’s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:
Type 1 or type 2 diabetes
Thyroid cancer
Pancreatitis
Kidney disease
Diabetic retinopathy
Depression
Suicidal thoughts or behavior
Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.
If you are pregnant: Ozempic should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Ozempic during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
If you are a female or male of reproductive potential: Discontinue Ozempic at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.
If you are breastfeeding: Ozempic was found in the milk of lactating rats. Tell your Good Life-affiliated provider if you are breastfeeding before you start Ozempic.
Pregnancy registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide (the active ingredient in Ozempic and Ozempic) during pregnancy. Pregnant women exposed to semaglutide and healthcare providers are encouraged to contact Novo Nordisk at 1-800-727-6500.
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
What are the most serious side effects that I or a caregiver should monitor for when taking Ozempic?
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
These serious side effects can occur with Ozempic. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.
Thyroid C-Cell Tumors: In mice and rats, semaglutide (the active ingredient in Ozempic and Ozempic) caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Ozempic causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza and Saxenda) after the drug was put on the market. Ozempic is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: If you have type 2 diabetes, tell your provider right away if you experience changes in vision.
Never Share a Pen: Pen-sharing poses a risk of infection.
Low Blood Sugar (hypoglycemia): Ozempic lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Acute Kidney Injury: In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.
Serious Allergic Reactions: Stop using Ozempic right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Acute Gallbladder Disease: Ozempic may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Increase in Heart Rate: Tell your provider right away if you have a racing heartbeat while at rest.
Suicidal Behavior and Ideation: You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
What are the most common side effects of Ozempic?
Nausea
Vomiting
Diarrhea
Stomach pain
Constipation
You are encouraged to report negative side effects of prescription products:
Contact Novo Nordisk Inc. at 1-833-934-6891
Contact FDA MedWatch at 1-800-FDA-1088 or visit www.fda.gov/medwatch
This information is not comprehensive. Please see the full Prescribing Information for complete safety information.
-
NAD+ injections are generally considered safe when administered properly. However, as with any medical treatment, there may be risks and potential side effects. Here are some important safety points to consider:
Injection Site Reactions: Mild bruising or soreness at the injection site is the most common side effect. This typically resolves on its own.
Allergic Reactions: Although rare, some individuals may experience allergic reactions to NAD+ injections. If you notice any signs of an allergic response (such as rash, itching, or difficulty breathing), seek immediate medical attention.
Interactions with Medications: NAD+ injections may interact with certain medications. Always inform your healthcare provider about any other drugs you’re taking to avoid potential interactions.
Underlying Health Conditions: Consult with your doctor before undergoing NAD+ therapy, especially if you have underlying health conditions. They can assess whether NAD+ injections are suitable for you.
Long-Term Effects: While NAD+ injections are generally well-tolerated, more research is needed to fully understand their long-term effects and safety profile.
-
Consult a Healthcare Professional:
Always consult with a qualified healthcare provider before starting any glutathione supplementation or treatment.
Discuss your medical history, allergies, and any existing health conditions.
Ensure that Glutathione injections are appropriate for your specific needs.
Injection Site Care:
If self-administering injections, follow proper techniques for injection site preparation and administration.
Sterilize the injection site and use a clean needle.
Rotate injection sites to prevent tissue damage or irritation.
Allergic Reactions:
Monitor for signs of allergic reactions, such as rash, itching, swelling, or difficulty breathing.
Seek immediate medical attention if you experience any adverse reactions.
Dosage and Frequency:
Follow the prescribed dosage and frequency recommended by your healthcare provider.
Avoid excessive doses, as high levels of glutathione can have unintended effects.
Side Effects:
Common side effects may include pain, redness, or swelling at the injection site.
Report any unusual or severe side effects promptly.
Remember that individual responses to glutathione injections can vary, and it’s essential to prioritize safety and follow professional guidance.
-
Vitamin B12 Injections:
1. Generally Safe: Vitamin B12 injections are considered very safe. They have no major side effects for most people.When taken at appropriate doses, vitamin B12 supplements are generally well-tolerated.
2. Allergic Reactions: While rare, some individuals may experience side effects due to allergic reactions or sensitivity. If younotice any adverse effects after receiving a B12 injection, consult with your doctor promptly.
3. Excess Elimination: Your body absorbs only the necessary amount of vitamin B12, and any excess is excreted through urine. Therefore, there’s minimal risk of toxicity.
4. Not for Everyone: B12 injections are typically recommended for individuals with a vitamin B12 deficiency. If you don’t have a deficiency, injections may not be necessary.
-
Indications:Lipotropic (MIC), B12, L-Carnitine injections are indicated as a supplement for individuals seeking to support their weight loss goals, boost energy levels, and promote overall well-being.
Contraindications:Lipotropic (MIC), B12, L-Carnitine injections are contraindicated in individuals with known hypersensitivity to any of the active ingredients or components of the injection solution.
Warnings and Precautions:
Allergic Reactions: Serious allergic reactions, including anaphylaxis, may occur with the use of Lipotropic (MIC), B12, L-Carnitine injections. Patients should be monitored for signs and symptoms of allergic reactions, and appropriate medical treatment should be initiated if necessary.
Injection Site Reactions: Localized injection site reactions, such as pain, swelling, or redness, may occur. Patients should be advised on proper injection techniques and instructed to rotate injection sites to minimize discomfort.
Interactions with Medications: Lipotropic (MIC), B12, L-Carnitine injections may interact with certain medications. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking before starting treatment with Lipotropic (MIC), B12, L-Carnitine injections.
Pregnancy and Lactation: The safety of Lipotropic (MIC), B12, L-Carnitine injections during pregnancy and lactation has not been established. Pregnant or breastfeeding women should consult with their healthcare provider before using Lipotropic (MIC), B12, L-Carnitine injections.
Adverse Reactions:Adverse reactions associated with Lipotropic (MIC), B12, L-Carnitine injections may include but are not limited to injection site reactions, allergic reactions, and gastrointestinal disturbances.
Patient Counseling Information:Patients should be counseled on the proper administration technique for Lipotropic (MIC), B12, L-Carnitine injections and advised to seek medical attention if they experience any adverse reactions. Patients should also be educated on the importance of maintaining a healthy lifestyle, including diet and exercise, in conjunction with the use of Lipotropic (MIC), B12, L-Carnitine injections for optimal results.
For additional information, consult with your healthcare provider.
-
NAD+ Nasal Spray is generally considered safe when administered properly. However, as with any medical treatment, there may be risks and potential side effects. Here are some important safety points to consider:
Side Effects: Nasal dryness or irritation, sneezing or transient burning sensation, headache, mild dizziness
Allergic Reactions: Although rare, some individuals may experience allergic reactions to NAD+ nasal. If you notice any signs of an allergic response (such as rash, itching, or difficulty breathing), dizziness or fainting, persistent fatigue or flu-like symptoms, seek immediate medical attention.
Interactions with Medications: NAD+ nasal spray may interact with certain medications. Always inform your healthcare provider about any other drugs you’re taking to avoid potential interactions.
Underlying Health Conditions: Consult with your doctor before undergoing NAD+ therapy, especially if you have underlying health conditions. They can assess whether NAD+ nasal is suitable for you.
Long-Term Effects: While NAD+ nasal spray is generally well-tolerated, more research is needed to fully understand their long-term effects and safety profile.
-
What are B12 MIC Lipotropic Injections? B12 MIC Lipotropic injections combine the benefits of Lipotropic compounds and vitamin B12. The “MIC” stands for Methionine, Inositol, and Choline—three essential amino acids that aid in breaking down and eliminating fat from the body. Vitamin B12 boosts energy levels, enhances metabolic function, and helps maintain optimal nerve health. Together, these elements create a powerful solution to improve weight loss results, boost energy, and enhance overall wellness.
Mechanism of Action:
B12 MIC Lipotropic injections work by combining the energy boost of Vitamin B12 with the fat-burning benefits of Lipotropic Complex.
The Lipotropic Complex (MIC) contains Methionine, Inositol, and Choline, which speed up metabolism and aid fat removal from the liver.
Vitamin B12 supports cell health, energy production, and red blood cell formation.
These components stimulate bile flow from the liver, promoting overall liver function and fat burning, leading to weight loss.
Health Benefits:
Boosting Energy Levels:
MIC B12 Lipotropic injections break down body fat, improve metabolism, and generate energy.
Individuals feel more energetic and productive in their daily lives.
Promoting Weight Loss:
B12 MIC Lipotropic injections optimize metabolism, boost energy, and facilitate fat breakdown.
Using them as part of a balanced weight loss plan can lead to promising results.
Safety Considerations:
B12 MIC Lipotropic injections are generally considered safe.
Potential side effects may include mild pain or discomfort at the injection site, nausea, or mild fatigue.
Always consult your doctor before starting any health-related treatment .
-
*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing tirzepatide are available.
WARNING
Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:
Severe nausea and/or vomiting resulting in dehydration - it is important to stay well hydrated and drink plenty of fluids while on this medication.
Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis.
Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below).
Pancreatitis: Severe pain in your abdomen or back that will not go away.
Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
Hepatitis/Elevated liver enzymes/Jaundice
Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy.
Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
Increasing heart rate
Worsening depression, behavior changes, or suicidality
Never share the tirzepatide with other people
Drug Interactions
As with other medications, oral tirzepatide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Oral tirzepatide delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting oral tirzepatide, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on oral tirzepatide.
Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.
To report suspected adverse reactions to oral tirzepatide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
In case of emergencies, please call 911 or go to the nearest emergency room.
Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.